ONCR News and Press, Oncorus Inc. From 08/04/22

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022 Company remains on track to submit IND for ONCR-021 in mid-2023 Ended quarter with $100.2 million in cash and cash equivalents to support next-genera...

-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes...

Gainers: Aero Clean Technologies AERC +49%. Houston American Energy (HUSA) +37%. Jan One JAN +37%. Oncorus (ONCR) +41%. Cytosorbents  (CTSO) +33%. Mirati Therapeutics MRTX +30%. Omega (OMGA) +27%. Codiak BioSciences (CDAK) +27%. Quantum Computing (QUBT) +26%. GitLab GTLB&#...

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will pa...

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will pre...

Oncorus (NASDAQ:ONCR) appointed 25-years industry veteran, Richard Wanstall as CFO. Most recently, he served as CFO and Treasurer for Aileron Therapeutics. "Oncorus is at a critical time in its development with key data readouts from ONCR-177 expected later this year, ongoing I...

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. “We are please...

Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022 Preclinical data presented for ONCR-021 and ONCR-788 at AACR Annual Meeting supports selectively self-amplifying vRNA/LNP immunotherapy platf...

– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy Platform has the potential to address challenges associated with IV-administered RNA-based oncology therapeutics – ...

Viral immunotherapies company Oncorus (NASDAQ:ONCR) said on Tuesday that it entered a loan and security agreement with K2 HealthVentures, a healthcare focused specialty finance company. Agreement provides Oncorus with up to $45M in multiple tranches upon the achievement of certain m...